

Docket No. X11057C

Serial Number: 10/785,326

Amendments to the Claims


Without prejudice or disclaimer, this listing of claims will replace all prior versions and listing of claims in this application.

1-18 (Cancelled)

19. (Currently amended) The method of Claim 14 145 wherein said term is composition is administered to said woman for at least six months.

20-144 (Cancelled)

145. (New) A method for reducing the likelihood of incurring or developing estrogen-dependent breast cancer in a post-menopausal woman diagnosed as being in need of such therapy which comprises administering orally to said woman a once-daily dose of a pharmaceutical composition wherein said composition comprises about 60 mg of the hydrochloride salt of a compound of the formula



146. (New) The method of claim 145 wherein said composition is administered to said woman chronically.

147. (New) The method of claim 145 wherein said incurrence or development of breast cancer is *de novo*.

148. (New) The method of claim 146 wherein said incurrence or development of breast cancer is *de novo*.

149. (New) The method of claim 145 wherein said woman is at increased risk of incurring or developing breast cancer.

150. (New) The method of claim 146 wherein said woman is at increased risk of incurring or developing breast cancer.

Docket No. X11057C

Serial Number: 10/785,326


151. (New) The method of claim 147 wherein said woman is at increased risk of incurring or developing breast cancer.

152. (New) The method of claim 148 wherein said woman is at increased risk of incurring or developing breast cancer.

Docket No. X11057C

Serial Number: 10/785,326

Respectfully submitted,



Gilbert T. Voy
Attorney for Applicants
Registration No. 43,972
Phone: 317-276-2966

Eli Lilly and Company
Patent Division/GTV
Lilly Corporate Center
Indianapolis, Indiana 46285

May 5, 2005